PT - JOURNAL ARTICLE AU - Amrollahi, Fatemeh AU - Shashikumar, Supreeth Prajwal AU - Yhdego, Haben AU - Nayebnazar, Arshia AU - Yung, Nathan AU - Wardi, Gabriel AU - Nemati, Shamim TI - Predicting Hospital Readmission among Patients with Sepsis using Clinical and Wearable Data AID - 10.1101/2023.04.10.23288368 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.10.23288368 4099 - http://medrxiv.org/content/early/2023/04/11/2023.04.10.23288368.short 4100 - http://medrxiv.org/content/early/2023/04/11/2023.04.10.23288368.full AB - Sepsis is a life-threatening condition that occurs due to a dysregulated host response to infection. Recent data demonstrate that patients with sepsis have a significantly higher readmission risk than other common conditions, such as heart failure, pneumonia and myocardial infarction and associated economic burden. Prior studies have demonstrated an association between a patient’s physical activity levels and readmission risk. In this study, we show that distribution of activity level prior and post-discharge among patients with sepsis are predictive of unplanned rehospitalization in 90 days (P-value<1e-3). Our preliminary results indicate that integrating Fitbit data with clinical measurements may improve model performance on predicting 90 days readmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementS.N. is funded by the National Institutes of Health (R01LM013998, R01HL157985, R35GM143121). S.N. and S.P.S are cofounders of a UCSD start-up, Healcisio Inc., which is focused on commercialization of advanced analytical decision support tools. G. W. is funded through an early career award from the National Institute of General Medical Sciences (K23GM146092).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Reviewing Board (IRB) approval was obtained prior to enrollment of patients in the AllofUs Research Program, the data has been deidentified, and has been made available in a secure enclave for research purposes.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe conducted a multicenter retrospective study using data available from the AllofUS (C2021Q3R6) data repository